Evaluates the use of recombinant hirudin as anticoagulant in critically ill patients with renal failure undergoing continuous hemodialysis. Treatment for heparin-induced thrombocytopenia type II; Consideration of risk of bleeding or clotting; Variation of hirudin dosage applied.